1. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
- Author
-
Méndez M, Matter H, Defossa E, Kurz M, Lebreton S, Li Z, Lohmann M, Löhn M, Mors H, Podeschwa M, Rackelmann N, Riedel J, Safar P, Thorpe DS, Schäfer M, Weitz D, and Breitschopf K
- Subjects
- Animals, Blood Glucose analysis, Cells, Cultured, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide-1 Receptor metabolism, HEK293 Cells, Humans, Hypoglycemic Agents chemical synthesis, Hypoglycemic Agents pharmacokinetics, Male, Mice, Mice, Inbred C57BL, Molecular Docking Simulation, Rats, Rats, Sprague-Dawley, Allosteric Regulation drug effects, Drug Design, Glucagon-Like Peptide-1 Receptor agonists, Hypoglycemic Agents chemistry, Hypoglycemic Agents pharmacology
- Abstract
The therapeutic success of peptidic GLP-1 receptor agonists for treatment of type 2 diabetes mellitus (T2DM) motivated our search for orally bioavailable small molecules that can activate the GLP-1 receptor (GLP-1R) as a well-validated target for T2DM. Here, the discovery and characterization of a potent and selective positive allosteric modulator (PAM) for GLP-1R based on a 3,4,5,6-tetrahydro-1 H -1,5-epiminoazocino[4,5- b ]indole scaffold is reported. Optimization of this series from HTS was supported by a GLP-1R ligand binding model. Biological in vitro testing revealed favorable ADME and pharmacological profiles for the best compound 19 . Characterization by in vivo pharmacokinetic and pharmacological studies demonstrated that 19 activates GLP-1R as positive allosteric modulator (PAM) in the presence of the much less active endogenous degradation product GLP1(9-36)NH
2 of the potent endogenous ligand GLP-1(7-36)NH2 . While these data suggest the potential of small molecule GLP-1R PAMs for T2DM treatment, further optimization is still required towards a clinical candidate.- Published
- 2020
- Full Text
- View/download PDF